BAUDAX BIO INC.(WI)DL-,01

As the market attempted to recover from a recent series of disappointing performances, biotechnology firm Baudax Bio (NASDAQ: BXRX ) represented a dramatic winner. Earlier Thursday morning, management disclosed that the U.S. Food and Drug Administration (FDA) granted its lead clinical candidate orphan drug designation. » Mehr auf investorplace.com

Shares of Baudax Bio added 80% after it announced its lead clinical candidate targeting Hemophilia A with inhibitors has been awarded orphan drug status by the United States Food and Drug Administration (FDA). Its lead candidate TI-168 is a FVIII specific Treg therapy designed to reliably and effectively address Hemophilia A patients with FVIII inhibitors. » Mehr auf proactiveinvestors.com

Baudax Bio (BXRX) soars on the acquisition of a private company, TeraImmune. The acquisition will help advance novel cell therapies for autoimmune diseases. » Mehr auf zacks.com